• Users Online: 166
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
Year : 2017  |  Volume : 8  |  Issue : 2  |  Page : 108-111

Retrospective analysis to assess the feasibility of escalated dose of nimotuzumab in patients with locally advanced head and neck cancer

1 Department of Radiation Oncology, Nanavati Super Speciality Hospital, Mumbai, Maharashtra, India
2 Medical Affairs, Biocon, Bengaluru, Karnataka, India
3 Medical Affairs and Clinical Development, Biocon, Bengaluru, Karnataka, India

Correspondence Address:
Nagraj Gururaj Huilgol
Department of Radiation Oncology, Nanavati Super Speciality Hospital, Mumbai, Maharashtra
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jrcr.jrcr_25_17

Rights and Permissions

Introduction: Head and neck cancer (HNC) has large worldwide prevalence and accounts for almost 5% among all types of cancers. Nimotuzumab is a humanized anti-epidermal growth factor receptor monoclonal antibody that has shown promising results in patients with HNC. The present retrospective case study aimed at investigating the response rate and adverse events (AEs) of a high dose of nimotuzumab in patients with HNC who are ineligible for platinum-based chemotherapy. Materials and Methods: Patients with locally advanced HNC who refused chemotherapy or were ineligible for platinum-based chemotherapy were analyzed in the study. Patients were given nimotuzumab along with radiotherapy (RT). The duration of each treatment cycle was 6 weeks. About 200 mg nimotuzumab was administered, twice weekly for 6 weeks. The patients who received at least one treatment cycle of targeted therapy and accompanied regular follow-ups were assessed for response rate measurements. Results: A total of six patients were enrolled in the study. A response rate of 100% was observed in the patients who completed the treatment. Complete and partial response was 60% and 40%, respectively, in HNC patients at the end of treatment. Three patients were reported with Grade II mucositis. No Grade III or IV AEs were observed in the patients. Conclusion: High dose of nimotuzumab along with RT enhanced response rate in patients with HNC who are ineligible for platinum-based chemotherapy without producing any additional toxicity.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded189    
    Comments [Add]    

Recommend this journal